Services
We collaborate with leading technology partners to extend imaging capability and deliver decision-ready data for clinical trials.
NVision
Bioxydyn partners with NVision Imaging Technologies to advance quantitative metabolic imaging in oncology. By combining NVision’s hyperpolarized metabolic imaging agents with Bioxydyn’s quantitative imaging biomarker expertise, we enable real-time, in vivo assessment of tumour metabolism.
This collaboration supports translational continuity from preclinical studies to early-phase clinical trials, helping sponsors generate robust pharmacodynamic insights and reduce development risk.
Our collaboration with Queen Square Analytics enables advanced AI methods for patient stratification with a focus on multiple sclerosis and Alzheimer's disease.
Together we deliver a comprehensive neurological clinical trial offering, including MR biomarker consultancy and imaging study design, imaging protocol development, worldwide site training and qualification, secure data handling and transfer, rigorous image QC with feedback loops, advanced analytics for stratification and subtyping, and comprehensive reporting with long-term data archiving.
Bioxydyn partners with Gold Standard Phantoms on the use of test objects (phantoms) for quantitative MRI and MRS applications. Reliable phantoms play an important role in site qualification and in scanner performance, particularly in multi-centre trials. Bioxydyn is also assisting GSP in their clinical trials of new phantoms for clinical use.